www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/3644

Title: Adriamycin, cyclophosphamide and vindesine (ACV) versus mitoxantrone, cyclophosphamide and vindesine (NCV) in advanced breast-cancer
Authors: JANSSENS, Jaak
CHIN, Y
DELEU, M
BONTE, J
STAELENS, Y
Issue Date: 1993
Publisher: INT INST ANTICANCER RESEARCH
Citation: ANTICANCER RESEARCH, 13(6B). p. 2477-2483
Abstract: The choice of chemotherapy for advanced breast cancer patients is based on both response rates and anticipated side effects. Two polychemotherapy regimens, ACV and NCV, were compared in an open study with 90 patients of whom 69 were evaluable both for efficacy and toxicity. Both ACV and NCV are active in metastatic breast cancer. ACV lends to more remissions in a relatively short time. NCV treatment results in a larger proportion of stable diseases. ACV causes more important alopecia, nausea and vomiting. NCV gives more anemia. The characteristics of both treatment results give the oncologist the opportunity to choose in particular clinical situations.
Notes: LIMBURGS ONCOL CTR,HASSELT GENK,BELGIUM. CATHOLIC UNIV LEUVEN,DEPT GYNECOL ONCOL,B-3000 LOUVAIN,BELGIUM. DIENST ONCOL H HARTZIEKENHUIS,TIENEN,BELGIUM.JANSSENS, JP, LIMBURGS UNIV CENTRUM,DR L WILLEMS INST,UNIV CAMPUS GEBOUW C,B-3590 DIEPENBEEK,BELGIUM.
URI: http://hdl.handle.net/1942/3644
ISI #: A1993NE37200023
ISSN: 0250-7005
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.